Prime Medicine Q2 net loss narrows on lower expenses
PRME•Pipeline programs advance
Prime Medicine said global clinical programs for Wilson disease and Alpha-1 Antitrypsin Deficiency are advancing, with initial data expected in 2027.
The company expects to initiate a global Phase 1/2 study of PM577a in the second half of 2026, with data in 2027. Prime Medicine also plans an IND/CTA submission for PM647 in the third quarter of 2026, with data expected in 2027.
Regulatory progress for PM359
Prime Medicine said it continues FDA engagement for PM359, targeting BLA submission in the first half of 2027.
The company said RMAT designation and ongoing FDA engagement for PM359 support expedited review and potential BLA submission in 2027.
Q2 net loss narrows on lower expenses
Prime Medicine said its second-quarter net loss narrowed year over year, driven by reduced research and development and general and administrative costs.
The company ended the second quarter with $108.8 million in cash and equivalents, providing runway into 2027.
Quarterly financial details and analyst coverage
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.24 |
| Q2 net loss | $42.11 million |
